New hope for scarred lungs: experimental drug aims to slow deadly fibrosis
NCT ID NCT07192939
Summary
This study is testing whether an experimental drug called HRS-9813 can slow the progression of pulmonary fibrosis, a disease that causes permanent scarring in the lungs. About 270 adults with either idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF) will receive either the drug or a placebo to see if it helps preserve lung function. The main goal is to see if the drug can slow the decline in a breathing test called FVC and reduce hospitalizations related to the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF AND PPF are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact
Conditions
Explore the condition pages connected to this study.